 FREMONT, Calif., Feb. 01, 2021 GLOBE NEWSWIRE -- Zosano Pharma Corporation NASDAQ:ZSAN, a clinical-stage biopharmaceutical company, today announced that early onset of action data for QtryptaTM, Zosanos investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference. 